EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (IS:ECILC) — Market Cap & Net Worth
Market Cap & Net Worth: EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC)
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (IS:ECILC) has a market capitalization of $1.31 Billion (TL58.56 Billion) as of May 2, 2026. Listed on the IS stock exchange, this Turkey-based company holds position #7939 globally and #61 in its home market, demonstrating a -3.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's stock price TL85.45 by its total outstanding shares 685260100 (685.26 Million). Review total liabilities of EIS Eczacibasi Ilac Sinai ve Finansal Ya to assess the company's total debt and financial obligations.
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS Market Cap History: 2015 to 2026
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's market capitalization history from 2015 to 2026. Data shows growth from $19.08 Million to $1.31 Billion (50.06% CAGR).
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.71x
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's market cap is 0.71 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $19.08 Million | $1.17 Billion | $67.65 Million | 0.02x | 0.28x |
| 2016 | $31.70 Million | $1.41 Billion | $184.80 Million | 0.02x | 0.17x |
| 2017 | $50.72 Million | $597.91 Million | $146.09 Million | 0.08x | 0.35x |
| 2018 | $33.13 Million | $692.09 Million | $240.12 Million | 0.05x | 0.14x |
| 2019 | $50.67 Million | $877.08 Million | $162.73 Million | 0.06x | 0.31x |
| 2020 | $103.54 Million | $909.13 Million | $322.09 Million | 0.11x | 0.32x |
| 2021 | $107.77 Million | $1.10 Billion | $755.06 Million | 0.10x | 0.14x |
| 2022 | $478.12 Million | $1.83 Billion | $4.18 Billion | 0.26x | 0.11x |
| 2023 | $660.08 Million | $9.36 Billion | $3.96 Billion | 0.07x | 0.17x |
| 2024 | $730.57 Million | $8.77 Billion | $1.02 Billion | 0.08x | 0.71x |
Competitor Companies of ECILC by Market Capitalization
Companies near EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS in the global market cap rankings as of May 2, 2026.
Key companies related to EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS Historical Marketcap From 2015 to 2026
Between 2015 and today, EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's market cap moved from $19.08 Million to $ 1.31 Billion, with a yearly change of 50.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | TL1.31 Billion | +4.46% |
| 2025 | TL1.26 Billion | +71.85% |
| 2024 | TL730.57 Million | +10.68% |
| 2023 | TL660.08 Million | +38.06% |
| 2022 | TL478.12 Million | +343.67% |
| 2021 | TL107.77 Million | +4.08% |
| 2020 | TL103.54 Million | +104.35% |
| 2019 | TL50.67 Million | +52.95% |
| 2018 | TL33.13 Million | -34.69% |
| 2017 | TL50.72 Million | +60.00% |
| 2016 | TL31.70 Million | +66.15% |
| 2015 | TL19.08 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.31 Billion USD |
| MoneyControl | $1.31 Billion USD |
| MarketWatch | $1.31 Billion USD |
| marketcap.company | $1.31 Billion USD |
| Reuters | $1.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses in Turkey and internationally. The Health segment is involved in the production, marketing, and sale of medicines related to human health and veterinary medicines. The Real Estate Development segment develops real estate properties; engages… Read more